SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical (NASDAQ: BSDM) today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The investor conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
“We are looking forward to attending our first institutional investor conference following our recently completed non-deal roadshow as we continue to broaden our institutional exposure”
William Barth, BSD Medical’s Chief Financial Officer, will provide an overview of BSD's business during the live presentation and will be available to participate in one-on-one meetings with institutional investors who are registered to attend the conference. The presentation will be webcast live. To access the webcast, please visit either the Events & Presentations tab on BSD’s website at http://investor.bsdmedical.com/events_and_presentations or www.rodm.com. The webcast replay will remain available for 90 days following the live presentation.
“We are looking forward to attending our first institutional investor conference following our recently completed non-deal roadshow as we continue to broaden our institutional exposure,” stated William Barth, Chief Financial Officer of BSD Medical.
Event: 15th Annual Rodman & Renshaw Global Investment Conference
Date: September 9, 2013
Presentation Time: 10:00 a.m. Eastern Time
Location: Room 7.01; Millennium Broadway Hotel in New York City
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.